Search Results - "Sroczynski G"

Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.

Authors: Sroczynski, G. Esteban, E. Conrads-Frank, A. et al.

Source: Journal of Viral Hepatitis. Jan2010, Vol. 17 Issue 1, p34-50. 17p. 6 Charts, 1 Graph.

Cost-effectiveness of primary HPV screening for cervical cancer in Germany – a decision analysis

Authors: Sroczynski, G. Schnell-Inderst, P. Mühlberger, N. et al.

Source: European Journal of Cancer. Jul2011, Vol. 47 Issue 11, p1633-1646. 14p.

Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Authors: Siebert U Sroczynski G Aidelsburger P et al.

Source: PharmacoEconomics. 2009, Vol. 27 Issue 4, p341-354. 14p.

Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health.

Authors: Mühlberger N Sroczynski G Esteban E et al.

Source: International Journal of Technology Assessment in Health Care; Apr2008, Vol. 24 Issue 2, p184-192, 9p

Prevention of breast&ovarian cancer in women with BRCA-1/2 mutations - A decision-analytic evaluation.

Authors: Hallsson, L. R. Sroczynski, G. Engel, J. et al.

Source: European Journal of Public Health. 2021 Supplement, Vol. 31, piii247-iii248. 2p.

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C.

Authors: Siebert, U. Sroczynski, G. Rossol, S. et al.

Source: Gut (0017-5749). Mar2003, Vol. 52 Issue 3, p425. 8p. 4 Charts, 1 Graph.

HTA170 Including Decision-Analytic Benefit-Harm Evaluation in HTA - Different Age Ranges and Screening Intervals in Breast Cancer Screening in Germany.

Authors: Sroczynski, G Hallsson, LR Mühlberger, N et al.

Source: Value in Health. 2022 Suppl, Vol. 25 Issue 12, pS329-S329. 1p.

HPR171 COVID 19 Vaccination - How to Support Decisions on Vaccination Prioritization for New Variants of Concern?

Authors: Jahn, B Sroczynski, G Bicher, M et al.

Source: Value in Health. 2022 Suppl, Vol. 25 Issue 12, pS263-S263. 1p.

CO4 How Can the Long-Term Benefits and Harms of Screening Be Transparently Quantified and Contrasted for Informed Decision-Making? Colorectal Cancer Screening for Persons at Familial Risk (FARKOR).

Authors: Sroczynski, G. Hallsson, L.R. Mühlberger, N. et al.

Source: Value in Health. 2022 Suppl, Vol. 25 Issue 12, pS17-S17. 1p.

EE131 Health-Economic Evaluation of Early Screening for Individuals Younger Than Age 50 with Familial Colorectal Cancer Risk Based on a Decision Analysis within the Farkor Study.

Authors: Sroczynski, G Hallsson, LR Mühlberger, N et al.

Source: Value in Health. 2022 Supplement, Vol. 25 Issue 7, pS360-S360. 1p.

P16 COVID-19 Vaccination Strategies Considering a Vaccine Adapted to a New Variant of Concern: A Decision-Analytic Modeling Study.

Authors: Jahn, B. Sroczynski, G. Bicher, M. et al.

Source: Value in Health. 2022 Supplement, Vol. 25 Issue 7, pS290-S290. 1p.

POSA172 How to Optimize COVID-19 Vaccination Considering Limited Vaccination Capacities: A Decision-Analytic Framework and Modeling Study.

Authors: Jahn, B Sroczynski, G Bicher, M et al.

Source: Value in Health. 2022 Supplement, Vol. 25 Issue 1, pS121-S121. 1p.

Evaluation of a targeted COVID-19 vaccination strategy for Austria–a decision-analytic modeling study.

Authors: Jahn, B. Sroczynski, G. Bicher, M. et al.

Source: European Journal of Public Health. 2021 Supplement, Vol. 31, piii367-iii367. 1/2p.

PCN55 Budget IMPACT of Implementing HPV Testing in Cervical Cancer Screening in Austria - a MODEL Based Analysis.

Authors: Sroczynski, G. Hallsson, L. Mühlberger, N. et al.

Source: Value in Health. 2020 Supplement 2, Vol. 23, pS431-S431. 1p.

PCN43 NEW CERVICAL CANCER SCREENING POLICY IN GERMANY - WHAT IS THE IMPACT ON THE BENEFIT-HARM BALANCE?

Authors: Sroczynski, G. Hillemanns, P. Siebert, U.

Source: Value in Health. 2019 Supplement 3, Vol. 22, pS443-S443. 1p.

PIN55 - Cost-Effectiveness Of Ombitasvir/Paritaprevir/Ritonavir With Or Without Dasabuvir For The Treatment Of Chronic Hepatitis C Patients Infected With Genotype 1 Or 4 In France.

Authors: Sroczynski, G Conrads-Frank, A Mühlberger, N et al.

Source: Value in Health. Nov/Dec2016, Vol. 19 Issue 7, pA416-A416. 1p.

PGI18 - Health-Economic Evaluation of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Treatment of Chronic Genotype 1 Hcv Infection in Germany.

Authors: Sroczynski, G Conrads-Frank, A Kühne, F et al.

Source: Value in Health. Nov/Dec2016, Vol. 19 Issue 7, pA512-A512. 1p.

MD2 - Towards Improved Cervical Cancer Primary Screening in Austria - A Decision-Analytic Benefit-Harm Analysis.

Authors: Sroczynski, G Esteban, E Widschwendter, A et al.

Source: Value in Health. Nov/Dec2016, Vol. 19 Issue 7, pA356-A356. 1p.

PMD55 - Cost-Effectiveness of Different Cervical Cancer Primary Screening Using Cytology, HPV Or P16/KI-67 Testing Alone Or in Combinations for The Austrian Health Care Context.

Authors: Sroczynski, G Esteban, E Widschwendter, A et al.

Source: Value in Health. Nov/Dec2016, Vol. 19 Issue 7, pA694-A694. 1p.

The Benefit-Harm Frontier of Different Primary Screening Strategies for Cervical Cancer in Germany.

Authors: Sroczynski, G. Esteban, E. Engel, J. et al.

Source: Value in Health. Nov2013, Vol. 16 Issue 7, pA574-A575. 0p.